Compare REAL & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REAL | VNDA |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 398.9M |
| IPO Year | 2019 | 2006 |
| Metric | REAL | VNDA |
|---|---|---|
| Price | $15.56 | $6.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $15.29 | $14.00 |
| AVG Volume (30 Days) | ★ 2.7M | 1.3M |
| Earning Date | 11-10-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $662,789,000.00 | $212,074,000.00 |
| Revenue This Year | $17.10 | $12.01 |
| Revenue Next Year | $10.96 | $21.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.30 | 11.12 |
| 52 Week Low | $4.61 | $3.81 |
| 52 Week High | $16.24 | $7.20 |
| Indicator | REAL | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 63.39 | 65.87 |
| Support Level | $14.02 | $6.15 |
| Resistance Level | $16.08 | $7.20 |
| Average True Range (ATR) | 0.75 | 0.47 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 72.83 | 83.17 |
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.